OTCMKTS:PLPRF

Plus Products Competitors

$0.52
-0.04 (-7.14 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.47
Now: $0.52
$0.59
50-Day Range
$0.54
MA: $0.69
$0.85
52-Week Range
$0.33
Now: $0.52
$1.15
Volume146,127 shs
Average Volume145,095 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Plus Products (OTCMKTS:PLPRF) Vs. ABAHF, ACRGF, APPB, AYRSF, CANB, and CNTMF

Should you be buying PLPRF stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Plus Products, including Abacus Health Products (ABAHF), Acreage (ACRGF), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Can B (CANB), and Cansortium (CNTMF).

Plus Products (OTCMKTS:PLPRF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Plus Products and Abacus Health Products' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Plus ProductsN/AN/AN/AN/AN/A
Abacus Health ProductsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Plus Products and Abacus Health Products, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Plus Products00103.00
Abacus Health Products0000N/A

Plus Products currently has a consensus price target of $1.50, suggesting a potential upside of 188.46%. Given Plus Products' higher possible upside, equities analysts plainly believe Plus Products is more favorable than Abacus Health Products.

Profitability

This table compares Plus Products and Abacus Health Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Plus ProductsN/AN/AN/A
Abacus Health ProductsN/AN/AN/A

Summary

Plus Products beats Abacus Health Products on 2 of the 2 factors compared between the two stocks.

Plus Products (OTCMKTS:PLPRF) and Acreage (OTCMKTS:ACRGF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Plus Products and Acreage's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Plus ProductsN/AN/AN/AN/AN/A
AcreageN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Plus Products and Acreage, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Plus Products00103.00
Acreage01202.67

Plus Products currently has a consensus price target of $1.50, suggesting a potential upside of 188.46%. Acreage has a consensus price target of $8.4333, suggesting a potential upside of 204.45%. Given Acreage's higher possible upside, analysts plainly believe Acreage is more favorable than Plus Products.

Profitability

This table compares Plus Products and Acreage's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Plus ProductsN/AN/AN/A
AcreageN/AN/AN/A

Summary

Acreage beats Plus Products on 2 of the 3 factors compared between the two stocks.

Plus Products (OTCMKTS:PLPRF) and Applied Biosciences (OTCMKTS:APPB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Plus Products and Applied Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Plus ProductsN/AN/AN/AN/AN/A
Applied BiosciencesN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Plus Products and Applied Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Plus Products00103.00
Applied Biosciences0000N/A

Plus Products currently has a consensus price target of $1.50, suggesting a potential upside of 188.46%. Given Plus Products' higher possible upside, equities analysts plainly believe Plus Products is more favorable than Applied Biosciences.

Profitability

This table compares Plus Products and Applied Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Plus ProductsN/AN/AN/A
Applied BiosciencesN/AN/AN/A

Summary

Plus Products beats Applied Biosciences on 2 of the 2 factors compared between the two stocks.

Plus Products (OTCMKTS:PLPRF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Plus Products and Ayr Strategies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Plus ProductsN/AN/AN/AN/AN/A
Ayr StrategiesN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Plus Products and Ayr Strategies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Plus Products00103.00
Ayr Strategies01602.86

Plus Products currently has a consensus price target of $1.50, suggesting a potential upside of 188.46%. Ayr Strategies has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. Given Plus Products' stronger consensus rating and higher possible upside, equities analysts plainly believe Plus Products is more favorable than Ayr Strategies.

Profitability

This table compares Plus Products and Ayr Strategies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Plus ProductsN/AN/AN/A
Ayr StrategiesN/AN/AN/A

Summary

Plus Products beats Ayr Strategies on 2 of the 3 factors compared between the two stocks.

Plus Products (OTCMKTS:PLPRF) and Can B (NASDAQ:CANB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Plus Products and Can B's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Plus ProductsN/AN/AN/AN/AN/A
Can BN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Plus Products and Can B, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Plus Products00103.00
Can B0000N/A

Plus Products currently has a consensus price target of $1.50, suggesting a potential upside of 188.46%. Given Plus Products' higher possible upside, equities analysts plainly believe Plus Products is more favorable than Can B.

Profitability

This table compares Plus Products and Can B's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Plus ProductsN/AN/AN/A
Can BN/AN/AN/A

Summary

Plus Products beats Can B on 2 of the 2 factors compared between the two stocks.

Plus Products (OTCMKTS:PLPRF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Valuation and Earnings

This table compares Plus Products and Cansortium's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Plus ProductsN/AN/AN/AN/AN/A
CansortiumN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Plus Products and Cansortium, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Plus Products00103.00
Cansortium00103.00

Plus Products currently has a consensus price target of $1.50, suggesting a potential upside of 188.46%. Cansortium has a consensus price target of $1.20, suggesting a potential upside of 18.81%. Given Plus Products' higher possible upside, research analysts clearly believe Plus Products is more favorable than Cansortium.

Profitability

This table compares Plus Products and Cansortium's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Plus ProductsN/AN/AN/A
CansortiumN/AN/AN/A

Summary

Plus Products beats Cansortium on 1 of the 1 factors compared between the two stocks.


Plus Products Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ABAHF
Abacus Health Products
0.4$4.84-5.4%$0.00N/A0.00Gap Up
Acreage logo
ACRGF
Acreage
1.2$2.77-0.0%$0.00N/A0.00
Applied Biosciences logo
APPB
Applied Biosciences
0.5$0.22-77.3%$0.00N/A0.00Increase in Short Interest
Gap Up
AYRSF
Ayr Strategies
1.4$21.26-0.0%$0.00N/A0.00
Can B logo
CANB
Can B
0.4$0.49-6.1%$0.00N/A0.00Gap Up
Cansortium logo
CNTMF
Cansortium
0.9$1.01-3.0%$0.00N/A0.00Gap Down
Charlotte's Web logo
CWBHF
Charlotte's Web
1.3$4.06-1.0%$0.00N/A0.00
Choom logo
CHOOF
Choom
0.5$0.10-10.3%$0.00N/A0.00Gap Up
CPHRF
Cipher Pharmaceuticals
1.2$1.09-2.8%$0.00N/A0.00Decrease in Short Interest
Gap Down
CLS Holdings USA logo
CLSH
CLS Holdings USA
0.7$0.22-4.5%$0.00N/A0.00News Coverage
Gap Up
Cosmos logo
COSM
Cosmos
0.5$5.40-1.9%$0.00N/A0.00High Trading Volume
Increase in Short Interest
Gap Down
Cresco Labs logo
CRLBF
Cresco Labs
1.5$12.17-2.7%$0.00N/A0.00Gap Up
Curaleaf logo
CURLF
Curaleaf
1.6$13.84-1.2%$0.00N/A0.00
HMDEF
DionyMed Brands
0.5N/AN/A$0.00N/A0.00High Trading Volume
Easton Pharmaceuticals logo
EAPH
Easton Pharmaceuticals
0.5$0.00-0.0%$0.00N/A0.00Decrease in Short Interest
Elixinol Global logo
ELLXF
Elixinol Global
0.8$0.14-0.0%$0.00N/A0.00Gap Up
EVIO logo
EVIO
EVIO
0.6$0.00-0.0%$0.00N/A0.00News Coverage
Gap Down
Flower One logo
FLOOF
Flower One
0.4$0.22-9.1%$0.00N/A0.00Gap Up
Golden Leaf logo
GLDFF
Golden Leaf
0.5$0.05-0.0%$0.00N/A0.00News Coverage
Green Growth Brands logo
GGBXF
Green Growth Brands
0.4$0.01-0.0%$0.00N/A0.00Gap Up
Green Thumb Industries logo
GTBIF
Green Thumb Industries
1.7$29.31-0.6%$0.00N/A0.00
GTEC logo
GGTTF
GTEC
0.6$0.62-3.2%$0.00N/A0.00Increase in Short Interest
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$2.82-0.7%$0.00N/A0.00
Hemp Naturals logo
HPMM
Hemp Naturals
0.6$0.01-0.0%$0.00N/A0.00
Hexo logo
HYYDF
Hexo
0.6N/AN/A$0.00N/A0.00
Hikma Pharmaceuticals logo
HKMPY
Hikma Pharmaceuticals
0.4$59.68-0.0%$0.00N/A0.00
iAnthus Capital logo
ITHUF
iAnthus Capital
0.6$0.22-0.0%$0.00N/A0.00Gap Down
Icanic Brands logo
ICNAF
Icanic Brands
0.6$0.32-0.0%$0.00N/A0.00Decrease in Short Interest
News Coverage
KNHBF
ICC International Cannabis
0.6N/AN/A$0.00N/A0.00
Invictus MD Strategies logo
IVITF
Invictus MD Strategies
0.6$0.04-0.0%$0.00N/A0.00Decrease in Short Interest
Gap Up
Isodiol International logo
ISOLF
Isodiol International
0.4$0.07-0.0%$0.00N/A0.00Gap Up
Khiron Life Sciences logo
KHRNF
Khiron Life Sciences
1.4$0.40-2.5%$0.00N/A0.00Decrease in Short Interest
KHTRF
Knight Therapeutics
1.2$4.22-0.2%$0.00N/A0.00High Trading Volume
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01-0.0%$0.00N/A0.00Increase in Short Interest
News Coverage
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.04-0.0%$0.00N/A0.00Gap Up
MediPharm Labs logo
MEDIF
MediPharm Labs
1.2$0.38-0.0%$0.00N/A0.00Analyst Report
Increase in Short Interest
MedMen Enterprises logo
MMNFF
MedMen Enterprises
0.8$0.30-6.6%$0.00N/A0.00Increase in Short Interest
Gap Up
MERCK Kommanditgesellschaft auf Aktien logo
MKKGY
MERCK Kommanditgesellschaft auf Aktien
0.5$35.76-1.1%$0.00N/A0.00Increase in Short Interest
MJardin Group logo
MJARF
MJardin Group
1.1$0.07-0.0%$0.00N/A0.00Gap Down
MYHI
Mountain High Acquisitions
0.5$0.02-0.0%$0.00N/A0.00Gap Up
PHCEF
Pharmacielo
0.7$1.25-7.2%$0.00N/A0.00Gap Down
Premier Biomedical logo
BIEI
Premier Biomedical
0.5$0.00-0.0%$0.00N/A0.00Gap Down
PCYN
Procyon
0.4$0.60-0.0%$0.00N/A0.00
Pure Global Cannabis logo
PRCNF
Pure Global Cannabis
0.7$0.01-0.0%$0.00N/A0.00Decrease in Short Interest
News Coverage
SANP
Santo Mining
0.5$0.01-0.0%$0.00N/A0.00News Coverage
Gap Down
Shionogi & Co., Ltd. logo
SGIOY
Shionogi & Co., Ltd.
0.5$13.39-1.2%$0.00N/A0.00Increase in Short Interest
Gap Down
DNPUF
Sumitomo Dainippon Pharma
0.5$17.40-0.0%$0.00N/A0.00News Coverage
TerrAscend logo
TRSSF
TerrAscend
1.7$10.02-0.0%$0.00N/A0.00Analyst Report
Increase in Short Interest
Gap Down
The Flowr logo
FLWPF
The Flowr
1.5$0.25-0.0%$0.00N/A0.00
The Supreme Cannabis logo
SPRWF
The Supreme Cannabis
1.0$0.30-3.3%$0.00N/A0.00Analyst Report
News Coverage
Gap Up
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.